Your browser doesn't support javascript.
loading
Impact of the blue-carba rapid test for carbapenemase detection on turnaround time for an early therapy against Pseudomonas aeruginosa.
da Cunha, Rick Shandler Rodrigues; Carniel, Eliana; Narvaez, Gabriel Azambuja; Dias, Cícero Gomes; Perez, Leandro Reus Rodrigues.
Afiliação
  • da Cunha RSR; Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • Carniel E; Post-graduate Program in Toxicology, Feevale University, Novo Hamburgo, RS, Brazil.
  • Narvaez GA; Department of Infectology, Mãe de Deus Hospital, Porto Alegre, RS, Brazil.
  • Dias CG; Department of Basic Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, RS, Brazil.
  • Perez LRR; Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: leandro.reus@gmail.com.
Am J Infect Control ; 49(3): 352-354, 2021 03.
Article em En | MEDLINE | ID: mdl-32814073
BACKGROUND: To determine the turnaround time from a blue-carba result until a final microbiological report (bacterial identification plus antimicrobial susceptibility profile) and to infer the impact of an early therapeutic intervention based on the blue-carba results. METHODS: Pseudomonas aeruginosa isolates were recovered from hospitalized patients from Porto Alegre, Brazil, and tested by blue-carba test. Time required for a blue-carba result, right after the sample processing, was compared with those required to get final report (specie identification and antimicrobial susceptibility profile) Isolates blue-carba positive were tested by phenotypically and genotypically for Klebsiella pneumoniae carbapenemase and metallo-ß-lactamase genes. RESULTS: A total of 199 isolates were analyzed and 23 (11.6%) were blue-carba positive and harboring the blaSPM-1-like gene. Fifty-two (26.1%) isolates were blue-carba negative but resistant to meropenem and/or imipenem. Polymyxin B and ceftolozane/tazobactam (this latter except for SPM-1 producers) were 100% active for all P. aeruginosa isolates, a blue-carba test allow an earlier intervention or adequacy of therapy. CONCLUSIONS: Early adequacy can be promoted by blue-carba test for 11.6% of SPM-1-producing P. aeruginosa isolates, polymyxin B could be prior associated and ceftolozane/tazobactam withdrawn from therapy. For the remaining isolates, empirical therapy involving ceftolozane/tazobactam can be maintained with greater likelihood of adequacy. An active communication between laboratory and clinical services is necessary to better explore these earlier blue-carba results, significantly reducing the time for a first intervention.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecções por Pseudomonas Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Am J Infect Control Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecções por Pseudomonas Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Am J Infect Control Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos